Search

Your search keyword '"Dizdarevic, Sabina"' showing total 231 results
Start Over Author "Dizdarevic, Sabina"
231 results on '"Dizdarevic, Sabina"'

1. Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study: Clinical Studies

Author

O’Sullivan, Joe M., Heinrich, Daniel, Castro, Elena, George, Saby, Dizdarevic, Sabina, Baldari, Sergio, Essler, Markus, Jong, Igle Jan de, Lastoria, Secondo, Hammerer, Peter G., Tombal, Bertrand, James, Nicholas D., Meltzer, Jeff, Sandström, Per, and Sartor, Oliver

Published
2025
Full Text
View/download PDF

4. Diagnostic Accuracy of a Convolutional Neural Network Assessment of Solitary Pulmonary Nodules Compared With PET With CT Imaging and Dynamic Contrast-Enhanced CT Imaging Using Unenhanced and Contrast-Enhanced CT Imaging

Author

Lucy Brindle, Anindo Banerjee, Callister, Matthew, Clegg, Andrew, Cook, Andrew, Cozens, Kelly, Crosbie, Philip, Dizdarevic, Sabina, Eaton, Rosemary, Eichhorst, Kathrin, Frew, Anthony, Groves, Ashley, Han, Sai, Jones, Jeremy, Kankam, Osie, Karunasaagarar, Kavitasagary, Kurban, Lutfi, Little, Louisa, Madden, Jackie, McClement, Chris, Miles, Ken, Moate, Patricia, Peebles, Charles, Pike, Lucy, Poon, Fat-Wui, Sinclair, Donald, Shah, Andrew, Vale, Luke, George, Steve, Riley, Richard, Lodge, Andrea, Buscombe, John, Green, Theresa, Stone, Amanda, Navani, Neal, Shortman, Robert, Azzopardi, Gabriella, Doffman, Sarah, Bush, Janice, Lyttle, Jane, Jacob, Kenneth, Horst, Joris van der, Sarvesvaran, Joseph, McLaren, Barbara, Gomersall, Lesley, Sharma, Ravi, Collie, Kathleen, O’Hickey, Steve, Tyler, Jayne, King, Sue, O’Brien, John, Srivastava, Rajiv, Lloyd-Jones, Hugh, Beech, Sandra, Scarsbrook, Andrew, Ashford-Turner, Victoria, Smith, Elaine, Mbale, Susan, Adams, Nick, Pottinger, Gail, Weir-McCall, Jonathan R., Debruyn, Elise, Harris, Scott, Qureshi, Nagmi R., Rintoul, Robert C., Gleeson, Fergus V., and Gilbert, Fiona J.

Published
2023
Full Text
View/download PDF

6. Imaging physiological ABC transporter expression and its relation to disease using Tc-99m-hexakis-methoxy-isobutyl isonitrile (Tc-99m-MIBI)

Author

Dizdarevic, Sabina

Subjects
610, A000 Medicine
Abstract

Tc-99m-MIBI is a substrate for ATP-binding cassette (ABC) transporter proteins, including P-glycoprotein (P-gp), and has been used to image their expression, mainly in cancer. Imaging P-gp expression may have a role in renal transplantation and investigating drug toxicity. The aim of the project was to develop a functional imaging assay for ABC-transporters using Tc-99m-MIBI.

Published
2015

7. Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE).

Author

Higano, Celestia S., Dizdarevic, Sabina, Logue, John, Richardson, Timothy, George, Saby, de Jong, Igle, Tomaszewski, Jeffrey J., Saad, Fred, Miller, Kurt, Meltzer, Jeffrey, Sandström, Per, Verholen, Frank, Tombal, Bertrand, and Sartor, Oliver

Subjects
*CASTRATION-resistant prostate cancer, *LEUCOCYTES, *SCIENTIFIC observation
Abstract

Background: Radium‐223 and taxane chemotherapy each improve survival of patients with metastatic castration‐resistant prostate cancer (mCRPC). Whether the radium‐223–taxane sequence could extend survival without cumulative toxicity was explored. Methods: The global, prospective, observational REASSURE study (NCT02141438) assessed real‐world safety and effectiveness of radium‐223 in patients with mCRPC. Using data from the prespecified second interim analysis (data cutoff, March 20, 2019), hematologic events and overall survival (OS) were evaluated in patients who were chemotherapy‐naive at radium‐223 initiation and subsequently received taxane chemotherapy starting ≤90 days ("immediate") or >90 days ("delayed") after the last radium‐223 dose. Results: Following radium‐223 therapy, 182 patients received docetaxel (172 [95%]) and/or cabazitaxel (44 [24%]); 34 patients (19%) received both. Seventy‐three patients (40%) received immediate chemotherapy and 109 patients (60%) received delayed chemotherapy. Median time from last radium‐223 dose to first taxane cycle was 3.6 months (range, 0.3–28.4). Median duration of first taxane was 3.7 months (range, 0–22.0). Fourteen patients (10 in the immediate and four in the delayed subgroup) had grade 3/4 hematologic events during taxane chemotherapy, including neutropenia in two patients in the delayed subgroup and thrombocytopenia in one patient in each subgroup. Median OS was 24.3 months from radium‐223 initiation and 11.8 months from start of taxane therapy. Conclusions: In real‐world clinical practice settings, a heterogeneous population of patients who received sequential radium‐223–taxane therapy had a low incidence of hematologic events, with a median survival of 1 year from taxane initiation. Thus, taxane chemotherapy is a feasible option for those who progress after radium‐223. Clinical Trial Registration: ClinicalTrials.gov identifier NCT02141438. Plain Language Summary: Radium‐223 and chemotherapy are treatment options for metastatic prostate cancer, which increase survival but may affect production of blood cells as a side effect.We wanted to know what would happen if patients received chemotherapy after radium‐223.Among the 182 men treated with radium‐223 who went on to receive chemotherapy, only two men had severe side effects affecting white blood cell production (neutropenia) during chemotherapy.On average, the 182 men lived for 2 years after starting radium‐223 and 1 year after starting chemotherapy.In conclusion, patients may benefit from chemotherapy after radium‐223 treatment without increasing the risk of side effects. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice

Author

Dizdarevic, Sabina, Petersen, Peter Meidahl, Essler, Markus, Versari, Annibale, Bourre, Jean-Cyril, la Fougère, Christian, Valdagni, Riccardo, Paganelli, Giovanni, Ezziddin, Samer, Kalinovský, Ján, Bayh, Inga, and Du, Yong

Published
2019
Full Text
View/download PDF

21. Association between body mass index (BMI) and [123I]Ioflupane (DaTSCAN) availabilities in patients with parkinsonism using single-photon emission computed tomography–computed tomography (SPECT-CT).

Author

Parekh, Puja, Begley, Patrick, Jessop, Maryam, Aplin, Mark, Missir, Elena, McMeekin, Helena, Raczek, Gosia, Singh, Nitasha, and Dizdarevic, Sabina

Subjects
SINGLE-photon emission computed tomography, BODY mass index, REGULATION of body weight, PARKINSONIAN disorders, NUCLEAR medicine, INVERSE relationships (Mathematics)
Abstract

Aim: [123I]Ioflupane (DaTSCAN) has a high binding affinity to the dopamine (DA) transporter (DaT) and tenfold less affinity to serotonin (5-HT) transporter (SERT). Both neurotransmitters are considered to contribute to body weight regulation. This study assesses the association between body mass index (BMI) and DaTSCAN availability in brain. Method: Scans from 74 consecutive patients who had undergone DaTSCAN single-photon emission computed tomography–computed tomography (SPECT-CT) were used to obtain semi- and absolute quantitative data in several volumes of interest (VOIs). Relative semi-quantitative specific binding ratios (SBRs) from Chang attenuated SPECT were obtained from GE DaTQUANT. Absolute normalised concentration (NC) was calculated from attenuation/scatter corrected SPECT-CT images, using an adapted version of the EARL Ltd (European Association of Nuclear Medicine (EANM) Research 4 Life) template. Scans were subdivided into either degenerative parkinsonism (abnormal = 49), borderline (n = 14) or scan without evidence of dopaminergic deficit (SWEDD = 11) using visual assessment and SBR values by two nuclear medicine consultants. Results: SBRs did not correlate with BMI. However, NC values correlated negatively in the entire cohort, with the strongest correlation in the frontal (r = − 0.649. p = 0.000), occipital (r = − 0.555, p = 0.000) regions and pons (r = − 0.555, p = 0.000). In the abnormal (n = 49) and SWEDD group (n = 11), NC of the frontal region was the most correlated with BMI (r = − 0.570, p = 0.000; r = − 0.813, p = 0.002, respectively). In the borderline group (n = 14), the left posterior putamen displayed the strongest correlation (r = − 0.765, p = 0.001). Conclusion: Absolute NC values demonstrate a strong inverse correlation with BMI, strongest in the extrastriatal regions. Due to the predominately non-overlapping distribution of DaT and SERT, this study suggests greater involvement of SERT in obesity with possible interplay with DA transmission. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Association between Body Mass Index (BMI) and [123I]-Ioflupane (DaTSCAN) availabilities in patients with parkinsonism using single-photon computed tomography-computed tomography (SPECT-CT)

Author

Parekh, Puja, primary, Begley, Patrick, additional, Jessop, Maryam, additional, Aplin, Mark, additional, Missir, Elena, additional, McMeekin, Helena, additional, Raczek, Malgorzata, additional, Singh, Nitasha, additional, and Dizdarevic, Sabina, additional

Published
2023
Full Text
View/download PDF

23. Diagnostic Accuracy of a Convolutional Neural Network Assessment of Solitary Pulmonary Nodules Compared With PET With CT Imaging and Dynamic Contrast-Enhanced CT Imaging Using Unenhanced and Contrast-Enhanced CT Imaging

Author

Weir-McCall, Jonathan R., primary, Debruyn, Elise, additional, Harris, Scott, additional, Qureshi, Nagmi R., additional, Rintoul, Robert C., additional, Gleeson, Fergus V., additional, Gilbert, Fiona J., additional, Lucy Brindle, Anindo Banerjee, additional, Callister, Matthew, additional, Clegg, Andrew, additional, Cook, Andrew, additional, Cozens, Kelly, additional, Crosbie, Philip, additional, Dizdarevic, Sabina, additional, Eaton, Rosemary, additional, Eichhorst, Kathrin, additional, Frew, Anthony, additional, Groves, Ashley, additional, Han, Sai, additional, Jones, Jeremy, additional, Kankam, Osie, additional, Karunasaagarar, Kavitasagary, additional, Kurban, Lutfi, additional, Little, Louisa, additional, Madden, Jackie, additional, McClement, Chris, additional, Miles, Ken, additional, Moate, Patricia, additional, Peebles, Charles, additional, Pike, Lucy, additional, Poon, Fat-Wui, additional, Sinclair, Donald, additional, Shah, Andrew, additional, Vale, Luke, additional, George, Steve, additional, Riley, Richard, additional, Lodge, Andrea, additional, Buscombe, John, additional, Green, Theresa, additional, Stone, Amanda, additional, Navani, Neal, additional, Shortman, Robert, additional, Azzopardi, Gabriella, additional, Doffman, Sarah, additional, Bush, Janice, additional, Lyttle, Jane, additional, Jacob, Kenneth, additional, Horst, Joris van der, additional, Sarvesvaran, Joseph, additional, McLaren, Barbara, additional, Gomersall, Lesley, additional, Sharma, Ravi, additional, Collie, Kathleen, additional, O’Hickey, Steve, additional, Tyler, Jayne, additional, King, Sue, additional, O’Brien, John, additional, Srivastava, Rajiv, additional, Lloyd-Jones, Hugh, additional, Beech, Sandra, additional, Scarsbrook, Andrew, additional, Ashford-Turner, Victoria, additional, Smith, Elaine, additional, Mbale, Susan, additional, Adams, Nick, additional, and Pottinger, Gail, additional

Published
2023
Full Text
View/download PDF

26. Protocol for a MULTI-centre feasibility study to assess the use of 99mTc-sestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)

Author

Warren, Hannah, Wagner, Thomas, Gorin, Michael A, Rowe, Steven, Holman, Beverley Fiona, Pencharz, Deborah, El-Sheikh, Soha, Barod, Ravi, Patki, Prasad, Mumtaz, Faiz, Bex, Axel, Kasivisvanathan, Veeru, Moore, Caroline M, Campain, Nicholas, Cartledge, Jon, Scarsbrook, Andrew, Hassan, Fahim, O'Brien, Tim S, Stewart, Grant D, Mendichovszky, Iosif, Dizdarevic, Sabina, Alanbuki, Ammar, Wildgoose, William H, Wah, Tze, Vindrola-Padros, Cecilia, Pizzo, Elena, Dehbi, Hakim-Moulay, Lorgelly, Paula, Gurusamy, Kurinchi, Emberton, Mark, Tran, Maxine GB, Warren, Hannah [0000-0002-4106-2705], Kasivisvanathan, Veeru [0000-0002-0832-382X], Moore, Caroline M [0000-0003-0202-7912], Stewart, Grant D [0000-0003-3188-9140], Vindrola-Padros, Cecilia [0000-0001-7859-1646], Gurusamy, Kurinchi [0000-0002-0313-9134], Emberton, Mark [0000-0003-4230-0338], and Apollo - University of Cambridge Repository

Subjects
Technetium Tc 99m Sestamibi, Tomography, Emission-Computed, Single-Photon, Urology, Urological tumours, HEALTH ECONOMICS, Kidney Neoplasms, Nuclear radiology, Humans, Feasibility Studies, Multicenter Studies as Topic, Prospective Studies, Radiopharmaceuticals, Tomography, X-Ray Computed
Abstract

Peer reviewed: True, Acknowledgements: We are grateful for the invaluable contribution provided by patient representatives. HW is funded by The Urology Foundation and Pan London Cancer Alliance (Royal Marsden Partners, North Central London Cancer Alliance, North East London Cancer Alliance, South East London Cancer Alliance and the NIHR BRCs). VK receives funding from Prostate Cancer UK and the John Black Charitable Foundation. GDS and IAM are supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) and GDS by the Cancer Research UK Cambridge Centre [C9685/A25177]. EP is supported by the NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) North Thames at Bart’s Health NHS Trust. Mark Emberton receives research support from the United Kingdom’s National Institute of Health Research (NIHR) UCLH / UCL Biomedical Research Centre. He was conferred NIHR Senior Investigator Status in 2015. MGBT receives research funding from NIHR, St Peter’s Trust, Royal Free Charity, RCS, Facing up 2 Kidney Cancer and Kidney Cancer UK. The views expressed are those of the authors and not necessarily those of the funders., INTRODUCTION: The incidence of renal tumours is increasing and anatomic imaging cannot reliably distinguish benign tumours from renal cell carcinoma. Up to 30% of renal tumours are benign, with oncocytomas the most common type. Biopsy has not been routinely adopted in many centres due to concerns surrounding non-diagnostic rate, bleeding and tumour seeding. As a result, benign masses are often unnecessarily surgically resected. 99mTc-sestamibi SPECT/CT has shown high diagnostic accuracy for benign renal oncocytomas and other oncocytic renal neoplasms of low malignant potential in single-centre studies. The primary aim of MULTI-MIBI is to assess feasibility of a multicentre study of 99mTc-sestamibi SPECT/CT against a reference standard of histopathology from surgical resection or biopsy. Secondary aims of the study include obtaining estimates of 99mTc-sestamibi SPECT/CT sensitivity and specificity and to inform the design and conduct of a future definitive trial. METHODS AND ANALYSIS: A feasibility prospective multicentre study of participants with indeterminate, clinical T1 renal tumours to undergo 99mTc-sestamibi SPECT/CT (index test) compared with histopathology from biopsy or surgical resection (reference test). Interpretation of the index and reference tests will be blinded to the results of the other. Recruitment rate as well as estimates of sensitivity, specificity, positive and negative predictive value will be reported. Semistructured interviews with patients and clinicians will provide qualitative data to inform onward trial design and delivery. Training materials for 99mTc-sestamibi SPECT/CT interpretation will be developed, assessed and optimised. Early health economic modelling using a decision analytic approach for different diagnostic strategies will be performed to understand the potential cost-effectiveness of 99mTc-sestamibi SPECT/CT. ETHICS AND DISSEMINATION: Ethical approval has been granted (UK HRA REC 20/YH/0279) protocol V.5.0 dated 21/6/2022. Study outputs will be presented and published nationally and internationally. TRIAL REGISTRATION NUMBER: ISRCTN12572202.

Published
2023

27. Protocol for a MULTI-centre feasibility study to assess the use of99mTc-sestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)

Author

Warren, Hannah, primary, Wagner, Thomas, additional, Gorin, Michael A, additional, Rowe, Steven, additional, Holman, Beverley Fiona, additional, Pencharz, Deborah, additional, El-Sheikh, Soha, additional, Barod, Ravi, additional, Patki, Prasad, additional, Mumtaz, Faiz, additional, Bex, Axel, additional, Kasivisvanathan, Veeru, additional, Moore, Caroline M, additional, Campain, Nicholas, additional, Cartledge, Jon, additional, Scarsbrook, Andrew, additional, Hassan, Fahim, additional, O'Brien, Tim S, additional, Stewart, Grant D, additional, Mendichovszky, Iosif, additional, Dizdarevic, Sabina, additional, Alanbuki, Ammar, additional, Wildgoose, William H, additional, Wah, Tze, additional, Vindrola-Padros, Cecilia, additional, Pizzo, Elena, additional, Dehbi, Hakim-Moulay, additional, Lorgelly, Paula, additional, Gurusamy, Kurinchi, additional, Emberton, Mark, additional, and Tran, Maxine G B, additional

Published
2023
Full Text
View/download PDF

28. Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis

Author

Barritt, Andrew W, primary, Das, Esther, additional, Morley, Nadine, additional, Seymour, Matthew, additional, Saha, Romi, additional, Vera, Jaime, additional, Vundavalli, Sriram, additional, Dizdarevic, Sabina, additional, Nicholas, Richard, additional, Berger, Joseph R, additional, and Fisniku, Leonora K, additional

Published
2022
Full Text
View/download PDF

34. Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study.

Author

James, Nicholas D., primary, Heinrich, Daniel, additional, Castro, Elena, additional, George, Saby, additional, Song, Daniel Y., additional, Dizdarevic, Sabina, additional, Baldari, Sergio, additional, Essler, Markus, additional, de Jong, Igle Jan, additional, Lastoria, Secondo, additional, Hammerer, Peter G., additional, Meltzer, Jeffrey, additional, Sandstrom, Per, additional, Verholen, Frank, additional, Tombal, Bertrand F., additional, O'Sullivan, Joe M., additional, and Sartor, A. Oliver, additional

Published
2022
Full Text
View/download PDF

35. Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling

Author

Gilbert, Fiona J, primary, Harris, Scott, additional, Miles, Kenneth A, additional, Weir-McCall, Jonathan R, additional, Qureshi, Nagmi R, additional, Rintoul, Robert C, additional, Dizdarevic, Sabina, additional, Pike, Lucy, additional, Sinclair, Donald, additional, Shah, Andrew, additional, Eaton, Rosemary, additional, Clegg, Andrew, additional, Benedetto, Valerio, additional, Hill, James E, additional, Cook, Andrew, additional, Tzelis, Dimitrios, additional, Vale, Luke, additional, Brindle, Lucy, additional, Madden, Jackie, additional, Cozens, Kelly, additional, Little, Louisa A, additional, Eichhorst, Kathrin, additional, Moate, Patricia, additional, McClement, Chris, additional, Peebles, Charles, additional, Banerjee, Anindo, additional, Han, Sai, additional, Poon, Fat Wui, additional, Groves, Ashley M, additional, Kurban, Lutfi, additional, Frew, Anthony J, additional, Callister, Matthew E, additional, Crosbie, Philip, additional, Gleeson, Fergus V, additional, Karunasaagarar, Kavitasagary, additional, Kankam, Osei, additional, and George, Steve, additional

Published
2022
Full Text
View/download PDF

37. Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.

Author

Barritt, Andrew W, Das, Esther, Morley, Nadine, Seymour, Matthew, Saha, Romi, Vera, Jaime, Vundavalli, Sriram, Dizdarevic, Sabina, Nicholas, Richard, Berger, Joseph R, and Fisniku, Leonora K

Subjects
PROGRESSIVE multifocal leukoencephalopathy, JOHN Cunningham virus, MULTIPLE sclerosis, IMMUNE reconstitution inflammatory syndrome, SEIZURES (Medicine), PEMBROLIZUMAB
Abstract

A 62-year-old man with relapsing-remitting multiple sclerosis developed progressive multifocal leukencephalopathy (PML) after 6 years on fingolimod. The fingolimod was immediately discontinued and preexisting mirtazepine increased. Three weeks later, with brain magnetic resonance imaging (MRI) appearances worsening and cerebrospinal fluid (CSF) JC virus (JCV) titres increasing, maraviroc was introduced. At 6 weeks, subtle punctate contrast enhancement raised the possibility of immune reconstitution inflammatory syndrome (IRIS), followed by a single focal-to-generalised tonic clonic seizure and a further deterioration in clinical disability. Mefloquine was commenced alongside three doses of pembrolizumab administered a month apart. Serial CSF examinations and several imaging modalities including spectroscopy and fused FDG-PET-MRI (18F-fluoro-deoxy-glucose–positron emission tomography–magnetic resonance imaging) were used to help distinguish between PML, PML-IRIS and rebound MS activity and guide optimal management at each stage. A handful of small, enhancing ovoid lesions developed between the first two doses of pembrolizumab, probably representative of a mild rebound phenomenon. A sustained improvement became obvious thereafter with CSF JCV-DNA undetectable 16 weeks following fingolimod withdrawal. To our knowledge, this is the first case of combined therapy and use of pembrolizumab in a fingolimod-associated PML. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. Comparative accuracy and cost-effectiveness of dynamic contrast-enhanced CT and positron emission tomography in the characterisation of solitary pulmonary nodules

Author

Gilbert, Fiona J, primary, Harris, Scott, additional, Miles, Kenneth A, additional, Weir-McCall, Jonathan R, additional, Qureshi, Nagmi R, additional, Rintoul, Robert Campbell, additional, Dizdarevic, Sabina, additional, Pike, Lucy, additional, Sinclair, Donald, additional, Shah, Andrew, additional, Eaton, Rosemary, additional, Jones, Jeremy, additional, Clegg, Andrew, additional, Benedetto, Valerio, additional, Hill, James, additional, Cook, Andrew, additional, Tzelis, Dimitrios, additional, Vale, Luke, additional, Brindle, Lucy, additional, Madden, Jackie, additional, Cozens, Kelly, additional, Little, Louisa, additional, Eichhorst, Kathrin, additional, Moate, Patricia, additional, McClement, Chris, additional, Peebles, Charles, additional, Banerjee, Anindo, additional, Han, Sai, additional, Poon, Fat-Wui, additional, Groves, Ashley M, additional, Kurban, Lutfi, additional, Frew, Anthony, additional, Callister, Matthew E J, additional, Crosbie, Phil A, additional, Gleeson, Fergus Vincent, additional, Karunasaagarar, Kavitasagary, additional, Kankam, Osei, additional, and George, Steve, additional

Published
2021
Full Text
View/download PDF

44. Comparative accuracy and cost-effectiveness of dynamic contrast-enhanced CT and positron emission tomography in the characterisation of solitary pulmonary nodules.

Author

Gilbert, Fiona J., Harris, Scott, Miles, Kenneth A., Weir-McCall, Jonathan R., Qureshi, Nagmi R., Campbell Rintoul, Robert, Dizdarevic, Sabina, Pike, Lucy, Sinclair, Donald, Shah, Andrew, Eaton, Rosemary, Jones, Jeremy, Clegg, Andrew, Benedetto, Valerio, Hill, James, Cook, Andrew, Tzelis, Dimitrios, Vale, Luke, Brindle, Lucy, and Madden, Jackie

Subjects
SOLITARY pulmonary nodule, POSITRON emission tomography computed tomography
Published
2022
Full Text
View/download PDF

47. A comparative analysis: international variation in PET-CT service provision in oncology—an International Cancer Benchmarking Partnership study

Author

Lynch, Charlotte, primary, Reguilon, Irene, additional, Langer, Deanna L, additional, Lane, Damon, additional, De, Prithwish, additional, Wong, Wai-Lup, additional, Mckiddie, Fergus, additional, Ross, Andrew, additional, Shack, Lorraine, additional, Win, Thida, additional, Marshall, Christopher, additional, Revheim, Mona-Eliszabeth, additional, Danckert, Bolette, additional, Butler, John, additional, Dizdarevic, Sabina, additional, Louzado, Cheryl, additional, Mcgivern, Canice, additional, Hazlett, Anne, additional, Chew, Cindy, additional, O’connell, Martin, additional, and Harrison, Samantha, additional

Published
2020
Full Text
View/download PDF

48. Impact of COVID-19 on nuclear medicine in the UK

Author

Dizdarevic, Sabina, primary, Abdulla, Mahdi, additional, Sewedy, Taha, additional, Weston, Charlotte, additional, Oxley, Caroline, additional, Croasdale, Jilly, additional, Redman, Stewart, additional, Vinjamuri, Sobhan, additional, Mayes, Christopher, additional, Flux, Glen, additional, Ward, Mike, additional, Graham, Richard, additional, and Buscombe, John, additional

Published
2020
Full Text
View/download PDF

49. Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy.

Author

Higano, Celestia S., primary, Harshman, Lauren C, additional, Dizdarevic, Sabina, additional, Logue, John, additional, Richardson, Timothy, additional, George, Saby, additional, Song, Danny, additional, de Jong, Igle J., additional, Tomaszewski, Jeffrey, additional, Saad, Fred, additional, Miller, Kurt, additional, Meltzer, Jeffrey, additional, Sandstrom, Per, additional, Tombal, Bertrand F., additional, and Sartor, A. Oliver, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results